Access to healthcare
R&D Strategy
While prioritizing the development of innovative drugs to address patients' unmet needs, HK inno.N also contributes to the stable supply of medicines by producing generics and improved drugs for patients who cannot afford original medications. Furthermore, the company consistently develops and manufactures shortage prevention drugs, such as smallpox vaccines and basic IV solutions, which are often avoided by pharmaceutical companies due to low profitability, ensuring that patients receive uninterrupted medical care.
Global expansion plan
HK inno.N strives to ensure that high-quality pharmaceuticals reach not only the domestic market but also the global market, making them accessible to more patients worldwide. Currently, the company supplies K-CAB as a finished product to local partners in developing countries such as Mexico and Indonesia, rapidly reaching GERD patients who previously had limited access to P-CAB class products.
Domestic pricing policy
Under Korean law, the price of pharmaceutical products is set by the government. Generics are set at about a 53.5% lower point compared to the original drugs at the time of registration. HK inno.N has been working especially hard towards building up its pipeline for generics that offer the same efficacy at the same dose but at a cheaper price. This allows better access for patients without the financial burden. HK inno.N also launched authorized generics that allow patients to be prescribed the same drug as the original but at a lower price and sooner than generics. Incrementally modified drugs are those that feature a better safety, efficacy and practicality profile compared to existing drugs that have been approved for the market. Through a proactive approach to developing incrementally modified drugs, HK inno.N makes it possible for patients to take safer, more cost-effective and convenient drugs
International pricing policy
HK inno.N sets the price of its products by taking into account consumer access to the products. Drugs that are essential to restoring patients’ health, such as antibiotic injections, fluids and treatment drugs for chronic diseases have their prices set by taking into account per capita GDP in each country, the healthcare infrastructure and the share of medical expenses compared against income levels. As such, the export prices to developing countries are intentionally set to be lower to contribute to improved access to healthcare in the export destination country.
impacts
R&D and launch of products for various diseases
| DALY(Disability Adjusted Life Year) Top 20 diseases with high DALY burden |
Product of HK inno.N | R&D of HK inno.N |
|---|---|---|
| 2. Depression | A-Xat CR, Lexler | |
| 4. Alzheimer’s disease | A-Pezil, A-Pezil FD | |
| 5. Diabetes | Dapa N, Basen, Glyone | diabetes medications, IN-B00009 |
| 7. Cardiovascular disease | Herben, Decaquinon, Digosin | antihyperlipidemic medications |
| 8. Stroke | inno.N Clopidgrel | |
| 9. Asthma | Lukio | |
| 10. Liver disease | Enteone | medications for metabolic dysfunction–associated fatty liver disease |
| 11. Cancer (lung cancer, breast cancer etc.) | Tarceone, Pemta Inj. | immuno-oncology medications |
| 13. other infectious diseases | Antibiotic injectable products | |
| 14. chronic kidney disease | Kremezin, Epokine | chronic kidney disease, renal failure medications |
| 16. Rheumatoid arthritis | Soleton | |
| 20. other neurological disorders | Vitamedin, Kabalin, Duloxta etc. |
Prevention of pharmaceutical counterfeiting
To prevent counterfeit drugs from entering the market and pose a threat to consumer health and trust in products, HK inno.N adopted a serial number system for drugs. HK inno.N assigns a product serial number to all ETC drugs and attaches barcodes and RFID tags, The barcodes and RFID tags are then used to transparently monitor how the drug is distributed throughout the market.
Improved local research capabilities through public- private partnerships
In association with Korea Trade-Investment Promotion Agency, or KOTRA, HK inno.N held a conference focusing on the improvement of R&D capabilities in low-to-middle income countries around the world. The conference served as a venue to introduce the latest developments in the treatment of gastrointestinal diseases and offered guidance on various treatment methods.
| Date | Venue | Audience | Theme |
|---|---|---|---|
| 2024.09.28 | Colombia | Gastrointestinal and internal doctors of Colombia | Para enfermedades relacionades con el á cido gástrico |
| 2024.11.16 | Korea | Gastrointestinal and internal doctors of China | Visit and consultation session for medical professionals of China |
| 2024.11.24 | Indonesia | Gastrointestinal and internal doctors of Indonesia | Advancements in Acid Related Disease Management |
| 2025.09.05 | Indonesia | Gastroenterologist of Indonesia | ANMA-IDDW 2025 Asia-Indonesia Gastrointestinal Conference |
| 2025.09.21 | China | Gastroenterologist of China | Shanghai IBD Research Progress Meeting |
| 2025.10.24 | China | Gastroenterologist of China | CGC 2025(The 25th Congress of Gastroenterology China) academic exchange of Chinese medical professionals |
Operation and support of pharmacovigilance system
HK inno.N carries out pharmacovigilance activities to ensure that patients can safely take all approved drugs. Information is continuously collected and compiled even after the drug is launched into the market, and information regarding consumer safety is included in the product inserts for healthcare professionals and consumers. All safety-related information are archived in the database to conduct regular safety assessments.
Meanwhile, a Safety Data Exchange Agreement, or SDEA is signed with all partner companies to support pharmacovigilance activities. Each company is asked to comply with the deadline for any reports of adverse events. This is also done for HK inno.N products that are launched into international markets.
Support for local manufacturers in foreign countries
HK inno.N provides technical support to its partner companies in developing countries to help them meet global manufacturing standards and enhance their capabilities. Through these efforts, the company ensures that more developing countries have access to safe pharmaceuticals.
Training of local healthcare professionals
To further boost its presence in the global pharmaceutical market, HK inno.N participates in various trade shows, presentations, IR sessions and partnership programs worldwide every year.
This opens up opportunities for the company to supply quality pharmaceutical products to new and emerging markets and help a larger number of countries and wider range of income classes to enjoy the benefits of advanced healthcare.
Of particular note is the information session on gastrointestinal diseases the company provides to local patients in these countries, along with an introduction to K-CAB which plays a role in helping treat such diseases. In addition, HK inno.N also takes part in the MOUs signed between academic associations of Korea specializing in gastrointestinal diseases and their overseas counterparts to promote wider range of collaboration. All such efforts work towards improving the quality of life of patients around the world. While the company supplies its biologic drug, Epokine Prefilled Injection (active ingredient: Erythropoietine) to a number of countries around the world, particular attention is given to the market of the Philippines as HK inno.N invites local healthcare professionals to Korea for an annual field trip on cutting-edge medical systems. This has allowed the drug to become available in the Philippines nationwide, and has offered a chance for many dialysis patients of the Philippines to benefit from high-quality drugs.
| Date | Place | Participants | Details |
|---|---|---|---|
| 2025.09.17 | India | Gastroenterologist of India | Korea-India gastrointestinal international academic exchange (4 cities) |
| 2025.10.28 | Republic of Korea | Gastroenterologist of China | SGI 2025(Korea-China gastrointestinal international academic exchange) |
Support for the socially vulnerable to improve access to healthcare information
HK inno.N works towards improving access to healthcare through various initiatives targeted at those with little access to medical information or the socially vulnerable who need guidance on drug administration. Programs include awareness-raising and support for drug administration. Walking inno.N, a step donation campaign to sponsor children suffering from diabetes and to raise awareness on organ donations, was started in 2021 and is still ongoing. In addition, a tailored guidance program for drug administration to minimize the chances of drug abuse or side effects from drug interactions, has also been underway, with a focus on the socially vulnerable who are on multiple drugs. The initiative also helps increase drug tolerance and efficacy of treatments for patients.
Activities to help regions lacking adequate medical infrastructure
HK inno.N works towards improving medical infrastructure to improve access to healthcare in regions where adequate medical infrastructure is lacking. In 2023, the company donated through PMCI approximately KRW 100 million worth of pharmaceutical products to the mobile clinic project* catering to the socially vulnerable in Cambodia. In addition, in collaboration with the Ministry of Oceans and Fisheries, HK inno.N operated a ‘remote island doctor’ project where remote medical consultation was offered to residents of remote islands. This allowed patients who found it difficult to make an in-person appointment at a healthcare facility to receive treatment and prescriptions. Through such projects, HK inno.N seeks to close the gap in access to healthcare across different regions and strengthen the capabilities of the public healthcare sector.
※ Mobile clinic project: A “medical service on wheels” where medical treatment and check-up buses are run to visit areas that have a higher concentration of the socially vulnerable.
Donation of drugs at home and abroad
Every year HK inno.N donates medical supplies and drugs to medical volunteering organizations to help increase access to healthcare in low-to-middle income countries. These drugs are used as part of medical volunteer work and as such, are not handed over directly to patients. Two medical volunteering organizations in Korea and three of their international counterparts are the recipients of annual donations. These organizations mostly carry out their volunteer work in remote areas of Korea where there are no hospitals nearby, as well as developing countries such as Indonesia, Tanzania and India and use HK inno.N products such as infectious disease treatments, rheumatoid arthritis treatments, and diabetes treatments in the process.